[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plaque-atherosclerotic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plaque-atherosclerotic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100544748","phase-4-intravascular-imaging-study-of-the-effect-of-inclisiran-on-plaque-in-patients-with-acute-myocardial-infarction-100544748",false,"NCT06372925","Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction","A Multi-Center, Randomized, Open-label, Parallel, Controlled Phase Ⅳ Clinical Trial to Evaluate the Effect of Inclisiran on Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarction and Elevated Low-density Lipoprotein Cholesterol","V-ACCELERATE","Inclusion Criteria:\n\n1. Male or female ≥ 18 and ≤ 75 years of age.\n2. Acute myocardial infarction (STEMI ≤ 24h\u002FNSTEMI ≤ 72h of onset of symptoms) with planned PCI.\n3. At least 1 major, non-infarct-related coronary artery (\"target vessel\") meet all of the following criteria judged by the investigator:\n\n1\\) Presence of atherosclerotic plaque with ≥ 20% and ≤ 50% diameter stenosis by coronary angiography.\n\n2\\) Target vessel deemed to be accessible to imaging catheters and suitable for intravascular imaging in the proximal (50 mm) segment (\"target segment\") 3) Target vessel is suitable for IVUS and OCT evaluation. 4) Not have undergone previous PCI within target vessel. 5) Not be a bypass graft or a bypassed native vessel. 4. Rapid LDL-C test value at screening period of:\n\n1. LDL-C \\> 1.8 mmol\u002FL if on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks upon signing ICF.\n2. LDL-C \\> 2.6 mmol\u002FL if not on stable dose of statin (with or without ezetimibe) for ≥ 4 weeks upon signing ICF.\n\n5\\. Written informed consent must be obtained.\n\nExclusion Criteria:\n\n1. Familial hypercholesterolemia or secondary hypercholesterolemia.\n2. Clinically instable AMI (hemodynamic or electrical instability).\n3. Left main disease, defined as ≥ 50% diameter stenosis of the left main coronary artery by coronary angiography.\n4. Three-vessel disease, defined as ≥ 70% diameter stenosis of 3 major epicardial coronary vessels or in major branches of these arteries by coronary angiography.\n5. Have a plan for interventional procedure within 12 months after signing ICF.\n6. Known intolerance to Atorvastatin OR known statin intolerance.\n7. Patients already on high-intensity statin including atorvastatin 40 or 80 mg or rosuvastatin 20 mg upon signing ICF.\n8. Patients not suitable for IVUS\u002FOCT evaluation (e.g., significant calcification , etc) judged by the investigator.\n9. Patients qualify for coronary artery bypass surgery at screening and history of coronary artery bypass surgery.\n10. Cardiac disorders:\n\n1\\) Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening; 2) Pacemaker or ICD in situ; and\u002For 3) Uncontrolled severe hypertension with systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg prior to randomization despite antihypertensive therapy.\n\n11\\. Rapid lipid test triglyceride (TG) level \\> 400mg\u002FdL (4.5 mmol\u002FL) at screening.\n\n12\\. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \\> 3x the upper limit of normal (ULN), or total bilirubin \\> 2x ULN before the randomization.\n\n13\\. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m2(Calculated according to the modified MDRD equation).\n\n14\\. Severe concomitant non-cardiovascular disease that carries the risk of reducing life expectancy to less than 2 years.\n\n15\\. Previous (within 90 days before randomization), current or planned treatment with a PCSK9 monoclonal antibody (mAb).\n\n16\\. Previous exposure to Inclisiran or any other non-mAb PCSK9-targeted therapy 2 years prior to randomization.\n\n17\\. Participation in another investigational device or drug study currently, or within 5 half-live (if drug) or 30 days whichever is longer, prior to randomization.\n\n18\\. History of hypersensitivity to any study drug or its excipients. 19. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study and\u002For put the participant at significant risk according to investigator's judgment.\n\n20\\. Pregnant or nursing (lactating) women. 21. Women of child-bearing potential, unless they are using effective methods of contraception during study treatment.\n\n22\\. Any conditions that according to the investigator could interfere with the conduct of the study.","ALL","18 Years","75 Years",{"count":21,"type":22},318,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This study is to evaluate the effect of Inclisiran on coronary atherosclerosis using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in patients with acute myocardial infarction and elevated low-density lipoprotein cholesterol (LDL-C).",[28],"Plaque, Atherosclerotic",[30,31,32,33,34,35],"Acute myocardial infarction,","Atherosclerotic plaque,","Inclisiran,","IVUS,","OCT,","PCI","RECRUITING","2026-05-29",{"date":39,"type":40},"2026-06-02","ACTUAL",{"date":42,"type":40},"2024-07-09",{"date":44,"type":22},"2027-01-26",{"name":46,"class":47},"Novartis Pharmaceuticals","INDUSTRY",20,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100575058","phase-4-comparison-of-moderate-intensity-statin-plus-ezetimibe-vs-high-intensity-statin-for-coronary-plaque-stabilization-100575058","NCT06767345","Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE Stabilization","Inclusion Criteria:\n\n* Adult men and women over the age of 18 years.\n* Patients with coronary artery disease undergoing a coronary intervention procedure using intravascular imaging.\n* At least one major native coronary artery (\"target vessel\") meeting all the following criteria for intracoronary imaging immediately following a qualifying PCI procedure:\n\n  * Angiographic evidence of coronary artery stenosis ≥30% by angiographic visual estimation.\n  * Target vessel is accessible to the imaging catheter and suitable for intracoronary imaging in the proximal 50 mm segment.\n  * Target vessel is not a bypass graft (aortic or arterial) or a bypassed graft vessel.\n  * Target vessel has not undergone PCI within the target segment.\n  * Target vessel is not a candidate for PCI at the time of the procedure or for 6 months thereafter (per investigator's judgment).\n* Patients who have provided written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Left main stem lesion: Left main coronary artery stenosis ≥50% by coronary angiographic visual estimation.\n* History of coronary artery bypass graft surgery (CABG).\n* Unstable clinical condition (hemodynamic or electrical instability).\n* Severe coronary artery calcification or tortuosity interfering with IVUS, NIRS, or evaluation.\n* Uncontrolled cardiac arrhythmia (recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response) not controlled by medication within 3 months prior to screening.\n* Active liver disease or liver dysfunction.\n* Severe renal dysfunction (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n* Known allergy to contrast media, heparin, aspirin, ticagrelor, or prasugrel.\n* Active infection or major hematologic, metabolic, or endocrine dysfunction as determined by the investigator.\n* Planned surgery within 12 months.\n* Currently enrolled in another investigational device or drug study.\n* Estimated life expectancy of less than 2 years.\n* Women of childbearing potential (under 50 years of age) who:\n\n  * Had their last menstrual period within the last 12 months.\n  * Have not had tubal ligation, oophorectomy, or hysterectomy.",{"count":57,"type":22},408,[25],"This study is a prospective, multicenter, randomized clinical trial aimed at comparing the effects of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy on coronary plaque stabilization. Using advanced imaging techniques such as near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS), the trial evaluates whether the combination therapy is non-inferior to monotherapy in stabilizing coronary plaques over 52 weeks. The primary endpoint is the percentage change in coronary atheroma volume (PAV) assessed by grayscale IVUS, with secondary outcomes including changes in lipid core burden, inflammatory markers, and clinical events like myocardial infarction and ischemic stroke. The study plans to enroll 408 patients undergoing coronary intervention across 7 domestic institutions, with rigorous follow-up protocols and adherence to international research guidelines.",[61,62,28],"Coronary Artery Disease","Atherosclerosis of Coronary Artery","2025-09-08",{"date":65,"type":40},"2025-09-15",{"date":67,"type":40},"2025-05-12",{"date":69,"type":22},"2028-06-25",{"name":71,"class":72},"Korea University Anam Hospital","OTHER",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":84,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":73},"100481520","optical-coherence-tomography-for-intracranial-atherosclerotic-stenosis-100481520","NCT05550077","Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis","Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis: a Prospective Registry Study (OCT-ICAS)","OCT-ICAS","Inclusion Criteria:\n\n* Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours\n* Stenotic degree ≥ 50%, measured by digital subtraction angiography\n* The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)\n\nExclusion Criteria:\n\n* Arteriovenous Malformation\n* Aneurysm",{"count":83,"type":22},400,"12 Months","OBSERVATIONAL","To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).",[88,89,28,90,91],"Intracranial Atherosclerosis","Optical Coherence Tomography","Artery Stenosis","Ischemic Stroke",[89,93,94,95],"Intravascular Imaging","Intracranial Atherosclerotic Stenosis","Percutaneous Transluminal Angioplasty and Stenting","2022-09-21",{"date":98,"type":40},"2022-09-23",{"date":100,"type":40},"2020-03-15",{"date":102,"type":22},"2027-12-31",{"name":104,"class":72},"jiaoliqun"]